Immunoreactivity analysis of Toxoplasma gondii recombinant antigen rSAG3 in sera from immunized BALB/c mice and tox-oplasmosis patients by Motazedian, M.H. et al.
  
Iran J Public Health, Vol. 45, No.7, Jul 2016, pp.911-916                                                   Original Article  
911                                                                                                        Available at:    http://ijph.tums.ac.ir 
 
 
Immunoreactivity Analysis of Toxoplasma 
oplasmosis Patients 
 
Mohammad Hossein MOTAZEDIAN 1, Bahram KAZEMI 2, Bahador SHAHRIARI 1, 
Mojgan BANDEHPOUR 2, *Khadijeh KHANALIHA 3 
 
1. Dept. of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 
2. Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
3. Research Center of Pediatric Infectious Diseases, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran 
 
*Corresponding Author: Email: khanaliha.kh@iums.ac.ir 
 






Toxoplasma gondii is an obligate intracellular proto-
zoan parasite with a global distribution among 
humans and mammals. Diagnosis of toxoplasmo-
sis is of considerable medical importance for 
human, especially pregnant women and immuno-
compromised individuals (1).  
T. gondii has a 43-kDa surface antigen (SAG3) 
that is exist on all of intrusive steps (2). SAG1 
and SAG3 are similar with 24% amino acid integ-
rity contain conservation of all of the cysteines in 
the mature protein and similar secondary and ter-
tiary structure which suggests similar folding for 
SAG1 and SAG3 (2, 3). SAGl is a tachyzoite-
specific antigen and highly immunogenic and is a 
good choice for vaccine (4). A strong immune 
response to SAG1 would allow the host to con-
trol the parasitic infection but cannot eliminate 
the bradyzoites (3).  
Abstract 
Background: The coccidian protozoa Toxoplasma gondii is an obligate intracellular parasite of humans and other warm-
blooded animals. Diagnosis of toxoplasmosis is of considerable medical importance for human, especially pregnant 
women and immunocompromised individuals. The apply of an Escherichia coli recombinant antigen(s) would be signifi-
cantly useful in developing standardization of the diagnostic tests and reducing their costs. In this study, immunoreac-
tivity of recombinant SAG3 against sera from immunized mice and human anti-T. gondii IgG positive patients was 
evaluated by western-blotting and enzyme immunoassay (EIA) in Department of Parasitology and Mycology, School 
of Medicine, Shiraz University of Medical Sciences in 2013. 
Methods: Three inbreed BALB/c female mice were obtained. Two mice were injected with rSAG3 and one was re-
mained untreated, as control. Sera from immunized mice and also pooled sera from IgG positive toxoplasmosis cases 
were evaluated with western-blotting. IgG antibody responses to recombinant SAG3 was measured by indirect ELISA 
against the negative control group.  
Results: The rSAG3 protein reacted with sera of immunized mice and sera from patients with anti-Toxoplasma IgG 
antibodies in western-blot analysis. The result of ELISA showed that, there was marked differences in the absorbance 
values between the recombinant SAG3 immunized mice and control group.  
Conclusion: The rSAG3 showed IgG reactivity with sera from immunized mice and anti-Toxoplasma IgG patients.  
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SAG3 (P43), common tachyzoite and bradyzoite 
antigen exist in the surface of both tachyzoite and 
bradyzoite of T. gondii and similar to SAG1 an-
chored to the membrane with glycosyl-
phosphatidylinositol groups (2). SAG3 is same as 
SAG1 in structure and function, and these two 
surface antigens have important roles in cellular 
invasion, attachment to cells and communication 
with host immune system (5). Tachyzoite mutants 
without SAG3 antigens is less virulent than wild-
type parasite, this subject demonstrate that SAG3 
is involved in the T. gondii infection process (6). 
Immunized mice with recombinant SAG3 could 
produce much more specific IgG2a antibody 
against T. gondii (7). Although in some studies, 
rSAG1 detected IgG reactivity in the chronic 
phase of infection (8-10), but few reports exist 
about reactivity of r SAG3.   
The aim of the present study was to investigate 
immunogenicity of T. gondii recombinant antigen, 
rSAG3 in BALB/c mice. 
  
Material and Methods 
 
P43 gene 
 SAG3 antigen has been cloned in pGEMEX1 
plasmid and sequenced in previous study in Cel-
lular and Molecular Biology Research Center, 
Shahid Beheshti University of Medical Science in 
2007(11). Recombinant pGEMEX-1 expression 
vector including P43 gene was confirmed by 
PCR, using specific primers and restriction analy-
sis by PstI restriction enzyme. PCR products 
were electrophoresed on 1.5% agarose gel and 
pGEMEX-1 containing the SAG3 insert 
(1158bp) was observed (12).   
 
Protein expression and purification 
The recombinant pGEMEX-1 plasmid was 
transformed into Escherichia coli JM109 competent 
cells according to Hanahan method (13).A single 
colony was inoculated in LBmedium (Merck, 
Germany) containing 100 µg/ml ampicillin and 
incubated overnight at 37 °C. Cells was subcul-
tured, using10-fold fresh LB medium containing 
100 µg/ml ampicillin and shacked at 200 rpm in 
37 °C until the OD600=0.7. The plasmid pro-
moter was induced by 1 mM Isopropyl β- D-1-
thiogalactopyranoside (IPTG) for 5 h. 
Sampling was done before and after induction in 
one hour intervals and finally the bacterial cells 
were harvested by centrifugation at 8000 rpm for 
15 min.  
Recombinant protein was purified, using The 
T7•Tag Affinity Purification Kit (Novagen, Mad-
ison Wisconsin, USA) according to the manufac-
turer’s method with some modifications that de-
scribed before (12).  
 
Preparation of anti SAG3 mouse hyper im-
mune serum 
 Three inbreed BALB/c female mice, 6-8 wk old 
and 18-22 g weight, were obtained from the ani-
mal house of Shiraz University of Medical Sci-
ences. Two mice were injected with rSAG3 and 
one was remained untreated, as control. The 
BALB/c mice were intraperitoneally injected 
with 50 µgr of purified rSAG3 in sterile PBS 
three times with one week interval. Complete 
Freund's adjuvant was used for the first injection 
and incomplete Freund's was used in subsequent 
injections. Mice sera were collected one week af-
ter the last injection. 
Serum samples were collected from different labor-
atories around Shiraz and Tehran and confirmed by 
using commercial IgG ELISA kits (Euroimmun, 
Lubeck, Germany). The pooled sera was prepared 
and used for western blotting analysis. 
This study was approved by the Ethics Commit-
tee of Shiraz University of Medical Sciences (Eth-
ic no.9153) in accordance with Helsinki Declara-
tion and guidelines. 
             
Western blotting and dot blotting analysis           
Immunoreactivity of recombinant SAG3 against 
sera from immunized mice and sera from anti-T. 
gondii IgG positive cases was evaluated with west-
ern-blotting. 
Recombinant SAG3 proteins was subjected to 
12% gradient SDS-PAGE with the molecular 
protein marker (Fermentas, Lithuania cat) (12), 
and western blot, was performed. The antigen 
was transferred from the gel into nitro-cellulose 
membrane (Schleicher and Schuell). All of trans-
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ferred bands were checked by staining the mem-
brane with Ponceau S stain (0.001 g/ml in 3% 
trichloroacetic acid). The membranes with blot-
ted antigen were cut into strips and blocked with 
5% (w/v) of skimmed milk in washing buffer (10 
mM Tris, 150 mM NaCl, and 0.05% Tween 20; 
pH 7.4) for 2 h. The strips were incubated with 
sera obtained injected mice and human anti-T. 
gondii IgG positive cases (1/100 dilution in wash-
ing buffer with 1% bovine serum albumin, BSA) 
for 2 h at room temperature. After 3 washes 
(each 15 min), the strips were incubated with 
HRP-conjugated goat anti-mouse IgG (Abcam, 
USA) and HRP-conjugated anti-human IgG 
(Sigma, USA) at a dilution of 1/2000 (in washing 
buffer+1% BSA) for 2 h at room temperature. 
The washes were done as described before, anti-
gen bounds were developed using diaminobenzi-
dine (DAB) substrate (0.1% H2O2+ 10 mg DAB 
in 10 ml (Tris-HCl, 10 mM, pH 7.4).  
Dot blot of recombinant SAG3 with sera ob-
tained from injected mice and untreated mouse 
was carried out to evaluate serum samples and 
conjugate dilution was used as same as described 
for western blotting analysis, recombinant SAG3 
boiled with loading buffer (SDS 0.003 M, Beta-
mercaptoethanol 0.5 M, Tris (pH=6.8) 0.5 M, 
5ml Glycerol ) and was blotted on nitro-cellulose 
membrane, after drying blocked with 5% (w/v) 
of skimmed milk and the strips were incubated 
with sera obtained from injected and untreated 
mice with 1/100 serum dilution in washing buff-
er with 1% bovine serum albumin (BSA) for 2 h 
at room temperature. The nitrocellulose strips 
were washed as it described before. The strips 
were incubated with HRP-conjugated goat anti-
mouse IgG (Abcam, USA) at a dilution of 
1/2000 (in washing buffer+1% BSA) for 2 h at 
room temperature. After washing, antigen 
bounds were developed using diaminobenzidine 
(DAB) substrate.  
  
Enzyme immunoassay 
 IgG antibody responses to recombinant SAG3 
was measured by indirect ELISA against the neg-
ative control group. 
Wells of ELISA micro plate were coated by 3 
μg/ml of recombinant SAG3 protein. Wells were 
washed three times with PBS containing 0.05% 
Tween 20 (PBST) and blocked with 3% skimmed 
milk in PBS-T. The mice sera samples diluted 
(1/100 and1/50 in PBST) and were added to the 
plate and incubated for 1.5 h. One hundred μL of 
HRP-conjugated goat anti-mouse IgG (Abcam, 
USA) was added to the palate and the plate was 
incubated for 1 h. The plate was washed as be-
fore and 100 μL of o-phenylenediamine dihydro-
chloride (OPD) (0.4 mg/ ml buffer) was added to 
the plate. Finally, the optical density was meas-
ured after 30 min at 490 nm wave length, using 




Immunoreactivity of rSAG3 with serum of im-
munized mice was confirmed by dot blot, and 
western- blot analysis and ELISA. Result of dot 
blot of recombinant SAG3 with sera of immun-
ized mice are shown in (Fig. 1). 
 
 
Fig. 1: Result of dot blot of recombinant SAG3 
with sera obtained injected mice 
1-Injected mouse; 2-Injected mouse; 3-Untreated 
mouse 
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As it can be seen in the blot, recombinant SAG3 
reacted with sera of immunized mice but not re-
acted with the serum of control mouse. 
The rSAG3 protein also reacted with sera of im-
munized mice and sera from patients with IgG 
anti Toxoplasma antibodies in western-blot analy-
sis and a band of almost 70 kDa (for SAG3, 
43kDa and T7 gen 10 as fusion protein, almost 
30kDa) and a band of almost 100 kDa were de-
tected by rSAG3-immunized mice and also sera 
of patients with IgG anti Toxoplasma antibody 
while these bands were not present in any of ei-
ther mice or human control sera, (Fig. 2). 
The result of ELISA showed that, there was 
marked differences in the absorbance values be-
tween the recombinant SAG3 immunized mice 
and control group. Mean of optical density in 
immunized mice was 0.78 while the mean value 




Fig. 2: Result of western blot using rSAG3 and sera 
obtained injected mice and human anti Toxoplasma 
sera; 1-marker; 2, 3 sera from injected mice; 4-serum 





Fig. 3: Result of IgG-ELISA using rSAG3 and sera obtained from injected mice ;1- serum obtained from injected 
mouse with 1:50 ,1:100 dilution;2- serum obtained from injected mouse with 1:50 ,1:100 dilution;3- serum obtained 




In this study we expressed and purified recombi-
nant SAG3 as a fusion protein with T7 gen10 in 
Escherichia coli and then BALB/c mice were in-
jected with the recombinant SAG3 protein in 
order to evaluate Immunoreactivity of this anti-
gen with sera obtained from injected mice and 
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pooled sera from patients with IgG anti Toxo-
plasma antibodies. 
In the western blot analysis two bands (70 KDa 
and 100 KDa) were seen in injected rSAG3 mice 
group and patients with IgG anti Toxoplasma an-
tibody but it is absent in untreated mouse as neg-
ative control. Recombinant SAG3 was produced 
in E. coli (JM109) seem to be as a mixture of 
monomer and dimmer forms in this study.  
The existence of both recombinant SAG1 mon-
omer and dimmer forms were reported in a study 
(13). 
In a study, serum with the high titer of IgG2 from 
mice infected with the C56, C37 virulent and 
non-virulent strain of Toxoplasma gondii immuno-
precipitated with P43 and P27 surface antigens. 
P43 was the prominent band precipitated by se-
rum from mice infected after 8 d with the C56 
strain of T.gondii (14). 
We obtained similar bands in sera obtained from 
injected recombinant SAG3 mice as a positive 
control after 3 wk and pooled sera from patients 
with IgG anti Toxoplasma antibody. 
Vaccination of mice with rSAG3 can induce par-
tial immunity against T. gondii infection concluded 
from the induction of Th1 type immune respons-
es and production of IgG2a antibody (7). 
In another study a DNA vaccine was produced 
by using two surface antigens SAG1 and SAG3 
from T. gondii and A2/B subunit of cholera tox-
in, as a genetic adjuvant and finally this vaccine 
was injected to BALB/c mice. Results of this 
study showed quiet more production of IgG an-
tibodies, proliferation of lymphocyte and produc-
tion of IFN-γ from spleen cells were induced in 
mice immunized with PSAG1/SAG3 compared 
to mice immunized with PSAG1 alone that result 
of this study demonstrates the role of SAG3 in 
combination with SAG1 in this vaccine (15). 
In other study, evaluate recombinant SAG1 for 
diagnosing of toxoplasmosis. Sensitivity and 
specificity of the recombinant SAG1 for the de-
tection IgG anti- Toxoplasma antibodies were 93% 
and 95%, and the sensitivity and specificity of 
this recombinant antigen for the detection of 
IgM were 87% and 95% in comparison with 
commercial ELISA respectively (16). The sensi-
tivity and specificity of the recombinant GRA7 
for diagnosing toxoplasmosis were 89% and 
90%, for the detection of IgG anti- Toxoplasma 
antibodies and were 96% and 90% for the detec-
tion of IgM respectively in another study (17). 
Diagnostic usefulness of three recombinant anti-
gens (SAG1, SAG2, and SAG3) of Toxoplasma 
gondii were evaluated and compared with com-
mercial ELISA kit .The results showed sensitivity 
and specificity of recombinant surface antigens 
for the detection of anti-Toxoplasma IgG in com-
parison with commercially ELISA were as fol-
lows: SAG1 (93.6% and 92.9%), SAG2 (100.0% 
and 89.4%), and SAG3 (95.4% and 91.2%), re-
spectively. Sensitivity and specificity of these re-
combinant antigens for the detection of anti-
Toxoplasma IgM were SAG1 (39.3% and 80%), 
SAG2 (64.3% and 83.3%) and SAG3 (17.9% and 
76.7%) respectively (18). These results showed 
rSAG3 had better performance for diagnosing of 
anti-Toxoplasma IgG than IgM. 
Production of IgG antibodies was induced in 
mice immunized with recombinant SAG3 and 
the result of IgG ELISA shows immunoreactivity 
of recombinant SAG3 in sera obtained from in-
jected recombinant SAG3 mice and sera from 
IgG positive toxoplasmosis patients .It seems 
recombinant SAG3 has the good performance in 




In the current study, rSAG3 showed IgG reac-
tivity with sera from immunized mice and T.gondii 
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